These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8366178)

  • 1. Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure.
    Ravis WR; Diskin CJ; Campagna KD; Clark CR; McMillian CL
    J Clin Pharmacol; 1993 Jun; 33(6):527-34. PubMed ID: 8366178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biotransformation of sulindac in end-stage renal disease.
    Gibson TP; Dobrinska MR; Lin JH; Entwistle LA; Davies RO
    Clin Pharmacol Ther; 1987 Jul; 42(1):82-8. PubMed ID: 3595070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulindac metabolism: the importance of an intact colon.
    Strong HA; Warner NJ; Renwick AG; George CF
    Clin Pharmacol Ther; 1985 Oct; 38(4):387-93. PubMed ID: 4042521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of cholestyramine resin administration on single dose sulindac pharmacokinetics.
    Malloy MJ; Ravis WR; Pennell AT; Hagan DR; Betagari S; Doshi DH
    Int J Clin Pharmacol Ther; 1994 Jun; 32(6):286-9. PubMed ID: 7921528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetics of sulindac in aged patients presenting with inflammatory joint disease].
    Mignot A; Lefebvre MA; Couet W; Dourthe C; Marechaud R; Fourtillan JB
    Therapie; 1989; 44(4):253-6. PubMed ID: 2595642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects.
    Berg AK; Mandrekar SJ; Ziegler KL; Carlson EC; Szabo E; Ames MM; Boring D; Limburg PJ; Reid JM;
    J Clin Pharmacol; 2013 Apr; 53(4):403-12. PubMed ID: 23436338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.
    Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ
    Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption of sulindac from a novel (Pro-SorbTM) liquid formulation.
    Kanfer I; Brown C; Konings M; Swarbrick J
    Biopharm Drug Dispos; 1996 Apr; 17(3):209-21. PubMed ID: 8983396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oral dosing paradigms (gavage versus diet) on pharmacokinetics and pharmacodynamics.
    Kapetanovic IM; Krishnaraj R; Martin-Jimenez T; Yuan L; van Breemen RB; Lyubimov A
    Chem Biol Interact; 2006 Dec; 164(1-2):68-75. PubMed ID: 17027946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulindac disposition when given once and twice daily.
    Swanson BN; Boppana VK; Vlasses PH; Holmes GI; Monsell K; Ferguson RK
    Clin Pharmacol Ther; 1982 Sep; 32(3):397-403. PubMed ID: 7049504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of age and disease on the pharmacokinetics and pharmacodynamics of sulindac.
    Sitar DS; Owen JA; MacDougall B; Hunter T; Mitenko PA
    Clin Pharmacol Ther; 1985 Aug; 38(2):228-34. PubMed ID: 4017423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of FMO3 Polymorphisms on Pharmacokinetics of Sulindac in Chinese Healthy Male Volunteers.
    Tang YJ; Hu K; Huang WH; Wang CZ; Liu Z; Chen Y; Ouyang DS; Tan ZR; Zhou HH; Yuan CS
    Biomed Res Int; 2017; 2017():4189678. PubMed ID: 28331852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. I. An application of pharmacokinetic model for reversible metabolism.
    Lin JH; Yeh KC; Duggan DE
    Drug Metab Dispos; 1985; 13(5):602-7. PubMed ID: 2865111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of single-nucleotide polymorphisms of FMO3 and FMO6 genes on pharmacokinetic characteristics of sulindac sulfide in premature labor.
    Park S; Lee NR; Lee KE; Park JY; Kim YJ; Gwak HS
    Drug Metab Dispos; 2014 Jan; 42(1):40-3. PubMed ID: 24173915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of sulindac. A dynamic old drug.
    Davies NM; Watson MS
    Clin Pharmacokinet; 1997 Jun; 32(6):437-59. PubMed ID: 9195115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulindac kinetics and effects on renal function and prostaglandin excretion in renal insufficiency.
    Klassen DK; Stout RL; Spilman PS; Whelton A
    J Clin Pharmacol; 1989 Nov; 29(11):1037-42. PubMed ID: 2600190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individual variability in concentrations of urinary sulindac sulfide.
    Brandli DW; Sarkissian E; Ng SC; Paulus HE
    Clin Pharmacol Ther; 1991 Dec; 50(6):650-5. PubMed ID: 1752108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of graded oral doses of sulindac in man.
    Mattila J; Mäntylä R; Vuorela A; Lamminsivu U; Männistö P
    Arzneimittelforschung; 1984; 34(2):226-9. PubMed ID: 6539116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of the active metabolite of nabumetone in renal dysfunction.
    Brier ME; Sloan RS; Aronoff GR
    Clin Pharmacol Ther; 1995 Jun; 57(6):622-7. PubMed ID: 7781261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis.
    Mahmoud NN; Boolbol SK; Dannenberg AJ; Mestre JR; Bilinski RT; Martucci C; Newmark HL; Chadburn A; Bertagnolli MM
    Carcinogenesis; 1998 Jan; 19(1):87-91. PubMed ID: 9472698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.